Skip to main content
. Author manuscript; available in PMC: 2011 Oct 15.
Published in final edited form as: J Mol Biol. 2010 Aug 25;403(1):131–147. doi: 10.1016/j.jmb.2010.08.033

Table 3. Comparative antigenicity of gp120Ba-L expressed in 293T cells in the presence or absence of 5 µM kifunensine.

Numbers shown indicated the fold increase or decrease in the 50% binding titer for the gp120Ba-L expressed in the presence of kifunensine compared to that produced in untreated cells. Bold type indicates a statistically significant difference (P < 0.05). Where the 50% binding titer did not fall within the range of ligand utilized, the fold-difference in absorbance at the maximal concentration of ligand is reported in parentheses. Epitope 1 – V3-loop; 2 – glycans; 3 – CD4bs; 4 –all regions (polyclonal immunoglobulin from HIV-1-infected patients or rabbit antisera to gp120).

Ligand Epitope Kifunensine
19b 1 3.43
447-52D 1 0.80
2G12 2 3.08
b12 3 82.06
F105 3 4.73
CD4-IgG2 3 6.08
15e 3 (9.14)
21h 3 (0.96)
HIVIg 4 1.46
ARP440 4 1.38